April 28th 2024
During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Dr. Ghassan Abou-Alfa on Possible Second-Line Treatments for HCC Patients
November 11th 2015Ghassan Abou-Alfa says serafnib is currently the only first-line treatment approved for HCC based on the SHARP trial, where the treatment showed improved survival in patients from 7.9 months to 10.7 months.
Watch
CF102 Receives Fast Track Designation for HCC
October 15th 2015The FDA has granted the A3AR agonist CF102 a fast track designation as a second-line treatment for patients with hepatocellular carcinoma. The drug is also planned to be tested in patients with rheumatoid arthritis and psoriasis.
Read More
Second-Line Treatments for Advanced Hepatocellular Carcinoma
October 13th 2015No established regimens exist for the treatment of patients with advanced hepatocellular carcinoma after failure of first-line treatment with the multikinase inhibitor sorafenib. Outcomes in the setting of sorafenib resistance or intolerance are poor, with a median expected overall survival for the placebo arms of second-line trials in the range of 7 to 8 months.
Read More
Role of MicroRNAs Evolving in the Diagnosis and Treatment of HCC
October 12th 2015Hepatocellular carcinoma has traditionally been an aggressive malignancy, with diagnosis taking place at later stages of disease and a poor prognosis in most patients. However, recent advances in molecular diagnostics and treatment show promise in changing the HCC clinical landscape.
Read More
HCC Survival Impacted by Radiofrequency Ablation Dwell Time
October 5th 2015A more than 25-month improvement in overall survival was seen with lyso-thermosensitive liposomal doxorubicin (LTLD; ThermoDox) combined with optimized (?45 minutes dwell time) radiofrequency ablation in patients with hepatocellular carcinoma.
Read More
Underused Ovarian Cancer Treatment Improves Overall Survival
August 7th 2015Almost 10 years following a study that proved intraperitoneal (IP), or abdominal, chemotherapy, along with intravenous (IV) therapy, may add 16 months or more to the lives of women with ovarian cancer, less than half of these patients at US hospitals receive this type of treatment
Read More
Transplant Versus Resection for Hepatocellular Carcinoma
July 23rd 2015Although liver transplantation may be a more ideal treatment option compared with resection for many patients with hepatocellular carcinoma (HCC), donor availability remains a major limiting factor to its widespread incorporation.
Read More
Managing the Elderly Patient With Unresectable HCC: Q and A With Pierre M. Gholam, MD, AGAF
July 15th 2015In a 2015, retrospective single-center study, patients with advanced HCC received systemic therapy with sorafenib combined with transarterial chemoembolization (TACE), and outcomes were compared between elderly (>70 years) and nonelderly (<70 years) patients.
Read More
Testing and Treatment for Hepatitis C in Patients With HCC
July 13th 2015Michael Manns, MD, chairman for the Department of Gastroenterology, Hepatology, and Endocrinology, Center of Internal Medicine, Hanover Medical School, Hanover, Germany, Vice President, United European Gastroenterology (UEG), discusses testing and treatment for Hepatitis C in patients with, as well as without, Hepatocellular carcinoma (HCC) liver cancer.
Watch
Immuno-Oncology Arrives in HCC
July 1st 2015The ASCO Annual Meeting is always packed with the latest and greatest advances in the field of oncology, and this year was no exception! The 2015 meeting had posted record-breaking numbers for abstract submissions and attendance, with over 37,000 individuals crowding the halls of the McCormick Place in Chicago.
Read More